908 Devices (MASS) Stock
Small maker of compact lab testing instruments. Here's the price, business snapshot, and what's worth knowing about 908 Devices in October 2026.
908 Devices Inc (ticker: MASS) develops compact analytical instruments used to detect and characterise chemicals and biomolecules across life sciences, pharmaceutical development, forensics and environmental testing. The company is small‑cap and focused on commercialising mass‑spectrometry and related platforms that aim to speed up analyses and reduce lab footprint. Investors should know this is a growth‑oriented business with a modest market capitalisation and a history of investment in product development; profitability and cash flow can be uneven as the company scales. Key considerations include technology adoption, recurring consumables or service revenue, competition from established instrument makers and sensitivity to research spending. Shares can be volatile; diversification, a long time horizon and understanding of execution risk are important. This is general educational information, not personalised investment advice—values can rise or fall and past performance is not a reliable guide to future returns.
908 Devices (MASS) Stock Forecast
Analyst price target, next 12 months
$11.75
+2.3% vs today's $11.49
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering 908 Devices have a consensus 12-month target of $11.75, above the current price of $11.49.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying 908 Devices Inc. stock, as its target price is higher than current value.
Financial Health
908 Devices is performing well with strong revenue and cash flow, indicating healthy business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growth through innovation
New compact mass‑spec and microfluidic platforms could open markets beyond traditional labs, though commercial adoption and execution risk remain.
Product‑led revenue
High‑value instruments paired with consumables and service can create recurring income, but scaling sales and support is resource‑intensive.
Diverse end markets
Applications span pharma, forensics and environment, offering diversification; demand can vary with research budgets and regulatory cycles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
